Literature DB >> 22098433

Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis.

Rein M J Hoedemakers1, Johannes F M Pruijt, Suzanne Hol, Elisa Teunissen, Henk Martens, Peter Stam, Roel Melsert, Henk Te Velthuis.   

Abstract

BACKGROUND: New monoclonal antibody-based assays for serum-free light chains (FLC) have become available.
METHODS: In a clinical study with 541 patients, the new N Latex FLC assays were compared with the Freelite FLC assays and immunofixation electrophoresis (IF).
RESULTS: Comparison of the different FLC kappa (κ) assays showed a slope of 0.99 with a deviation of 5.0%, rs=0.92, for FLC lambda (λ) a slope of 1.22, deviation 13.8%, rs=0.90 and for the κ/λ ratio a slope of 0.72, deviation -4.6%, rs=0.72. The concordance for the FLC κ assays was 91%, for FLC λ 85% and κ/λ ratio 95%. The clinical sensitivity and specificity of the κ/λ ratios in the study were comparable: 60% and 99% for the N Latex FLC assay and 61% and 97% for the Freelite assay. In IF-FLC positive samples, the N Latex FLC κ/λ ratio scored 20/23 (87%) samples outside the reference range and Freelite 21/23 (91%). For IF-FLC negative samples, N Latex FLC assay κ/λ ratio scored 338/350 (97%) within the reference range and Freelite scored 332/350 (95%).
CONCLUSIONS: The concordance scores and the clinical sensitivity and specificity of the new N Latex FLC assays and Freelite assays appeared comparable, but there are some differences in measurement of concentrations between the methods.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22098433     DOI: 10.1515/CCLM.2011.793

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  9 in total

1.  Serum free light chain quantitative assays: Dilemma of a biomarker.

Authors:  Giovanni Cigliana; Francesca Gulli; Cecilia Napodano; Krizia Pocino; Elena De Santis; Luigi Colacicco; Iole Cordone; Laura Conti; Umberto Basile
Journal:  J Clin Lab Anal       Date:  2017-04-26       Impact factor: 2.352

2.  Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease.

Authors:  Yang Yang; Xiaoyan Han; Gaofeng Zheng; Zhen Cai
Journal:  Health Sci Rep       Date:  2019-02-05

3.  Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies.

Authors:  Giovanni Cigliana; Eleonora Torti; Francesca Gulli; Elena De Santis; Maria Teresa Dell'Abate; Luigi Colacicco; Francesco Pisani; Laura Conti; Umberto Basile
Journal:  J Exp Clin Cancer Res       Date:  2015-04-23

4.  Comment on "Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy".

Authors:  Antony R Parker; Oscar Berlanga; Stephen Harding
Journal:  Biomed Res Int       Date:  2015-03-12       Impact factor: 3.411

5.  Effect of specimen type on free immunoglobulin light chains analysis on the Roche Diagnostics cobas 8000 analyzer.

Authors:  Louis S Nelson; Bryan Steussy; Cory S Morris; Matthew D Krasowski
Journal:  Springerplus       Date:  2015-12-08

6.  Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases.

Authors:  Rocco Sabatino; Antonio Perrone; Marco Cuomo; Sandra Liotti; Vittoria Barchiesi; Monica Cantile; Ernesta Cavalcanti
Journal:  Int J Mol Sci       Date:  2017-04-12       Impact factor: 5.923

7.  How to quantify monoclonal free light chains in plasma cell disorders: which mass spectrometry technology?

Authors:  Caroline Moreau; Charles R Lefevre; Olivier Decaux
Journal:  Ann Transl Med       Date:  2020-08

8.  Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy.

Authors:  Han-Sung Kim; Hyun Soo Kim; Kyu-Sung Shin; Wonkeun Song; Hyo Jung Kim; Hyeong Su Kim; Min-Jeong Park
Journal:  Biomed Res Int       Date:  2014-05-27       Impact factor: 3.411

9.  Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity.

Authors:  Klaus Berek; Gabriel Bsteh; Michael Auer; Franziska Di Pauli; Astrid Grams; Dejan Milosavljevic; Paulina Poskaite; Christine Schnabl; Sebastian Wurth; Anne Zinganell; Thomas Berger; Janette Walde; Florian Deisenhammer; Harald Hegen
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.